Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Andexanet alfa - Alexion AstraZeneca Rare Disease

Drug Profile

Andexanet alfa - Alexion AstraZeneca Rare Disease

Alternative Names: ALXN 2070; ANDEXXA; AndexXa; Coagulation factor Xa (recombinant), inactivated-zhzo; IndexXa; Ondexa; Ondexxya; PRT-064445; PRT-4445; PRT-44545; r-antidote; Recombinant factor-Xa-Portola; rfXa-inhibitor-antidote

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Portola Pharmaceuticals
  • Developer Alexion AstraZeneca Rare Disease
  • Class Antidotes; Antihaemorrhagics; Disulfides; Recombinant proteins
  • Mechanism of Action Blood coagulation stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Haemorrhage
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Haemorrhage

Most Recent Events

  • 01 Oct 2023 Janssen Pharmaceuticals is now called Johnson & Johnson Innovative Medicine (Janssen Pharmaceuticals website, October 2023)
  • 03 Jul 2023 Registered for Haemorrhage in Australia (IV)
  • 05 Jun 2023 AstraZeneca plans to submit regulatory filings to convert from conditional to full approval of andexanet alfa in the US and EU
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top